Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B.
Open Access
- 1 November 1991
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 266 (32) , 21386-21391
- https://doi.org/10.1016/s0021-9258(18)54649-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Molecular Basis of Different Forms of Metachromatic LeukodystrophyNew England Journal of Medicine, 1991
- Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-length cDNA, and regions of amino acid identity with arylsulfatases A and CGenomics, 1990
- Transcription of the dystrophin gene in human muscle and non-muscle tissuesNature, 1988
- An Improved Method for Prenatal Diagnosis of Genetic Diseases by Analysis of Amplified DNA SequencesNew England Journal of Medicine, 1987
- Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell AnemiaScience, 1985
- Restriction sites containing CpG show a higher frequency of polymorphism in human DNACell, 1984
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979
- Transfer of purified herpes virus thymidine kinase gene to cultured mouse cellsCell, 1977
- Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux-Lamy syndromeBiochemical and Biophysical Research Communications, 1974
- Maroteaux-lamy disease (mucopolysaccharidosis VI), subtype A: Deficiency of a N-acetylgalactosamine-4-sulfataseBiochemical and Biophysical Research Communications, 1974